Latest developments and achievements

News

Stay informed about the latest developments and achievements from TRICALS. Here we will report about our progress and the accomplishments of our large scale collaboration. Browse and read the latest news to stay updated along our journey to find a treatment for ALS.

Results ADORE study: no effect of medication
Results ADORE study: no effect of medication
The pharmaceutical company Ferrer has announced their first results of the ADORE…
Stay in [u]touch[/u]

Stay in touch

Would you like to keep up to date with the latest news from TRICALS? Click on the button below to subscribe to our newsletter

34th International Symposium on ALS/MND
34th International Symposium on ALS/MND
From 6 to 8 December 2023, more than 1300 people from all…
3FM Serious Request takes action for ALS Foundation Netherlands
3FM Serious Request takes action for ALS Foundation Netherlands
3FM Serious Request is taking action for the ALS Foundation Netherlands during…
Over 200 patients participate in Lighthouse II study worldwide
Over 200 patients participate in Lighthouse II study worldwide
The Lighthouse II study is a phase 3 clinical trial that compares…
ENCALS consensus statement on NurOwn
ENCALS consensus statement on NurOwn
Background Given the interest around the use of stem cells in ALS,…
Story behind the participant: Peter Ambühl
Story behind the participant: Peter Ambühl
Many clinical trials are looking for participants. In this new interview series,…
Apellis reports discontinuation of MERIDIAN study
Apellis reports discontinuation of MERIDIAN study
Pharmaceutical company Apellis has announced the discontinuation of the open-label phase of…
Recording of virtual meeting – Adherence and retention in ALS clinical trials
Recording of virtual meeting – Adherence and retention in ALS clinical trials
On March 22, 2023, TRICALS organised its first virtual meeting: ‘Adherence and retention…
COURAGE-ALS trial discontinued due to disappointing results
COURAGE-ALS trial discontinued due to disappointing results
The company Cytokinetics has announced early termination of the COURAGE-ALS study. An…
TRICALS consensus statement on Tofersen
TRICALS consensus statement on Tofersen
OPINION: The consensus view of TRICALS neurologists is that Tofersen shows clear…